Damon Runyon Researchers

Meet Our Scientists
Christopher E. Barbieri, MD, PhD

Prostate cancer is a clinically variable disease – some patients do well, while others do very poorly – and recent studies have shown clear molecular subtypes of prostate cancer that may explain this variability. Some subtypes of prostate cancer have underlying defects in repairing their DNA, making them potentially sensitive to therapies that exploit this deficiency. Dr. Barbieri [MetLife Foundation Clinical Investigator] is a surgeon scientist whose overall goal is to translate our understanding of the molecular basis of prostate cancer into near term benefits for patients. He will investigate the response to novel therapies for prostate cancer in patients undergoing surgical therapy for early stage disease, and define the genomic alterations that predict which cancers will be sensitive to these agents. Defining the response and the predictors of new agents in early, untreated prostate cancer will change the paradigm of how we treat men with the disease, allowing a precision medicine approach.

Project title: "Presurgical trials to target distinct subclasses of localized prostate cancer"
Institution: Weill Cornell Medicine
Named Award: MetLife Foundation Clinical Investigator
Award Program: Clinical Investigator
Sponsor(s) / Mentor(s): Lewis C. Cantley, PhD
Cancer Type: Prostate
Research Area: Pharmacogenomics and Biomarkers